Ticker >

Sequent Scientific share price

Sequent Scientific Ltd.

NSE: SEQUENT BSE: 512529 SECTOR: Pharmaceuticals & Drugs  77k   409   88

115.30
-4.45 (-3.72%)
BSE: 28 Mar 04:01 PM

Price Summary

Today's High

₹ 123

Today's Low

₹ 114.9

52 Week High

₹ 155.45

52 Week Low

₹ 69.78

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2875.97 Cr.

Enterprise Value

2894.89 Cr.

No. of Shares

24.94 Cr.

P/E

0

P/B

2.69

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  42.81

CASH

0.18 Cr.

DEBT

19.1 Cr.

Promoter Holding

52.79 %

EPS (TTM)

₹  -0.19

Sales Growth

1.39%

ROE

-0.61 %

ROCE

-0.68%

Profit Growth

-141.08 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.39%
3 Year-0.69%
5 Year16%

Profit Growth

1 Year-141.08%
3 Year-165.8%
5 Year-143.15%

ROE%

1 Year-0.61%
3 Year1.42%
5 Year1.5%

ROCE %

1 Year-0.68%
3 Year1.81%
5 Year1.88%

Debt/Equity

0.0191

Price to Cash Flow

76.19

Interest Cover Ratio

-2.87823318742539

CFO/PAT (5 Yr. Avg.)

2.19971616565604

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 52.79 0
Sep 2023 52.79 0
Jun 2023 52.79 0
Mar 2023 52.79 0
Dec 2022 52.79 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 20.932577885017 days.
  • The company has a high promoter holding of 52.79%.

 Limitations

  • The company has shown a poor profit growth of -165.800562237448% for the Past 3 years.
  • The company has shown a poor revenue growth of -0.686217352233975% for the Past 3 years.
  • Company has a poor ROE of 1.41680680670184% over the past 3 years.
  • Company has a poor ROCE of 1.81041968310547% over the past 3 years
  • The company has a low EBITDA margin of 0.460267582188537% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 206.9041.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 57 46.6 40.42 49.12 42.21
Total Expenditure 65.75 52.64 49.49 56.82 46.36
Operating Profit -8.75 -6.05 -9.07 -7.7 -4.16
Other Income 7.62 8.01 9.7 9.87 13.44
Interest 0.72 0.87 0.98 1.21 1.15
Depreciation 2.15 2.33 2.43 2.35 2.05
Exceptional Items 0 0 -6.25 0 0
Profit Before Tax -3.99 -1.23 -9.03 -1.4 6.09
Tax -2.77 0.42 -2.23 -0.48 1.51
Profit After Tax -1.23 -1.65 -6.8 -0.92 4.58
Adjusted EPS (Rs) -0.05 -0.07 -0.27 -0.04 0.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 166.26 227.33 265.46 219.63 222.69
Total Expenditure 163.57 206.84 241.5 231.59 249.09
Operating Profit 2.69 20.49 23.96 -11.97 -26.4
Other Income 13.96 16.31 31.3 38.86 28.29
Interest 3.22 5.04 2.68 1.61 2.51
Depreciation 7.22 8.95 9.13 9.59 9.12
Exceptional Items 0 0 -2.56 0 0
Profit Before Tax 6.2 22.81 40.89 15.69 -9.75
Tax -1.38 1.47 8.77 0.89 -3.67
Net Profit 7.59 21.34 32.11 14.8 -6.08
Adjusted EPS (Rs.) 0.31 0.86 1.29 0.6 -0.24

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 49.37 49.67 49.67 49.67 49.89
Total Reserves 868.42 836.54 979.84 991.41 1008.48
Borrowings 20.61 15.17 0 0 0
Other N/C liabilities 15.6 -3.67 4.81 19.26 12.44
Current liabilities 79.87 105.24 96.62 89.56 70.24
Total Liabilities 1033.87 1002.96 1130.94 1149.9 1141.04
Assets
Net Block 52.43 69.41 65.78 66.9 56.72
Capital WIP 0.03 3.72 4.34 1.4 2.2
Intangible WIP 0 0 0 0 0
Investments 788.16 738.95 685.11 658.47 632.47
Loans & Advances 84 66.37 230.43 267.66 355.34
Other N/C Assets 21.84 0.55 0.29 0.6 10.65
Current Assets 87.41 123.95 144.99 154.86 83.66
Total Assets 1033.87 1002.96 1130.94 1149.9 1141.04
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 6.2 22.81 43.45 15.69 -9.75
Adjustment -2.19 1.74 1.12 -6.38 -0.49
Changes in Assets & Liabilities 70.32 7.84 -25.47 1.81 48.68
Tax Paid -0.54 -2.19 -16.76 -1.75 -0.7
Operating Cash Flow 73.8 30.2 2.34 9.36 37.75
Investing Cash Flow -114.06 -17.69 16.55 -4.25 -50.7
Financing Cash Flow 40.34 -10.71 -21.33 7.25 0.24
Net Cash Flow 0.07 1.81 -2.44 12.36 -12.71

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 52.79 52.79 52.79 52.79 52.79
ca harbor investments 52.79 52.79 52.79 52.79 52.79
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 47.21 47.21 47.21 47.21 47.21
ashoka whiteoak icav - as... - - - - 1.64
investor education and pr... 0.01 0.01 - - 0.01
public sector pension inv... - - 1.07 - 1.14
quant mutual fund - quant... - - - - 4.67
turnaround opportunities ... - - - - 1.15
unit trust of india inves... - - - - 3.33
investor education and pr... - - 0.01 0.01 -
ashoka india opportunitie... 1.64 1.64 1.64 - -
unit trust of india inves... 3.33 3.33 3.33 - -
icici lombard general ins... 1.21 1.21 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Sequent Scientific - Quaterly Results13 Feb 2024, 8:53PM Sequent Scientific - Quaterly Results13 Feb 2024, 8:53PM Sequent Scientific to sell plot located in Ambernath Industrial Area8 Feb 2024, 6:19PM Sequent Scientific informs about transcript of earnings call13 Nov 2023, 5:17PM Sequent Scientific - Quaterly Results6 Nov 2023, 10:02PM Sequent Scientific - Quaterly Results6 Nov 2023, 10:02PM USFDA completes inspection at Sequent Scientific’s Visakhapatnam manufacturing facility 25 Sep 2023, 10:37AM Sequent Scientific gets nod to sell API facility in Tarapur15 Sep 2023, 11:43AM Sequent Scientific informs about rectification of inadvertent typographical error17 Aug 2023, 12:34PM Sequent Scientific informs about audio recording of earnings call11 Aug 2023, 4:21PM Sequent Scientific - Quaterly Results10 Aug 2023, 10:13PM Sequent Scientific - Quaterly Results10 Aug 2023, 10:13PM Sequent Scientific informs about appointment of director8 Aug 2023, 2:16PM Sequent Scientific - Quaterly Results23 May 2023, 8:16PM Sequent Scientific - Quaterly Results23 May 2023, 8:16PM Sequent Scientific informs about conference call17 May 2023, 11:02AM Sequent Scientific informs about non-applicability of large corporate entity 11 May 2023, 5:23PM Sequent Scientific informs about certificate14 Apr 2023, 3:46PM Sequent Scientific informs about trading window closure30 Mar 2023, 1:06PM Sequent Scientific terminates share purchase agreement with Tineta 9 Mar 2023, 11:30AM Sequent Scientific informs about earnings call transcript21 Feb 2023, 4:40PM Sequent Scientific - Quaterly Results14 Feb 2023, 5:56PM Sequent Scientific - Quaterly Results14 Feb 2023, 5:56PM Sequent Scientific informs about transcript of earnings call14 Nov 2022, 5:19PM Sequent Scientific gets nod to acquire 100% stake in Tineta Pharma8 Nov 2022, 12:58PM Sequent Scientific - Quaterly Results7 Nov 2022, 8:36PM Sequent Scientific - Quaterly Results7 Nov 2022, 8:36PM Sequent Scientific informs about earnings call transcript16 Aug 2022, 5:06PM Sequent Scientific - Quaterly Results8 Aug 2022, 9:36PM Sequent Scientific - Quaterly Results8 Aug 2022, 9:36PM Sequent Scientific - Quaterly Results25 May 2022, 9:08PM Sequent Scientific - Quaterly Results25 May 2022, 9:08PM Sequent Scientific informs about allotment of equity shares under ESOP26 Apr 2022, 4:59PM Sequent Scientific informs about postal ballot notice11 Apr 2022, 12:24PM Sequent Scientific acquires entire stake in Nourrie2 Mar 2022, 11:19AM Sequent Scientific informs about acquisition2 Mar 2022, 10:34AM Sequent Scientific - Quaterly Results11 Feb 2022, 8:06PM Sequent Scientific - Quaterly Results11 Feb 2022, 8:06PM Sequent Scientific informs about press release15 Jan 2022, 12:16PM Sequent Scientific informs about change in directorate15 Jan 2022, 11:51AM Sequent Scientific consolidates residual stake in Evance Group12 Jan 2022, 2:23PM Sequent Scientific’s arm inks pact to acquire 100% stake in Nourrie16 Dec 2021, 3:46PM Sequent Scientific informs about press release16 Dec 2021, 1:12PM Sequent Scientific informs about disclosure of related party transactions27 Nov 2021, 2:27PM Sequent Scientific - Quaterly Results1 Nov 2021, 7:54PM SeQuent Scientific gets EUGMP approval for tablets dosage manufacturing line in Turkey15 Jul 2021, 9:23AM Sequent Scientific informs about press release15 Feb 2021, 10:33AM SeQuent Scientific gets ‘Certificate of Suitability’ approval for Diclazuril API28 Jan 2021, 4:20PM Sequent Scientific informs about analyst meet28 Jan 2021, 3:32PM SeQuent Scientific launches Citramox LA in EU 10 Dec 2020, 2:48PM

Sequent Scientific Stock Price Analysis and Quick Research Report. Is Sequent Scientific an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sequent Scientific and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sequent Scientific cash from the operating activity was Rs 37.746 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sequent Scientific has a Debt to Equity ratio of 0.0191 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sequent Scientific , the EPS growth was -140.919771735482 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sequent Scientific has OPM of -11.8566585086557 % which is a bad sign for profitability.
     
  • ROE: Sequent Scientific have a poor ROE of -0.609179371262765 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sequent Scientific is Rs 115.5. One can use valuation calculators of ticker to know if Sequent Scientific share price is undervalued or overvalued.
Last Updated on:
Brief about Sequent Scientific

Sequent Scientific Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Sequent Scientific Limited is a leading animal health company based in India. The company focuses on developing, manufacturing, and marketing a wide range of veterinary products that promote animal health and increase productivity. Sequent Scientific Ltd. operates through two business segments, namely Animal Health and Specialty Chemicals.

The Animal Health segment of Sequent Scientific Ltd. offers a comprehensive range of innovative medicines, vaccines, and nutrition products for livestock and companion animals. The company has a global footprint, with a presence in over 100 countries, and is committed to ensuring animal health and welfare across the world.

The Specialty Chemicals segment of Sequent Scientific Ltd. serves a wide range of industries, including agrochemicals, pharmaceuticals, and personal care. The segment produces a variety of specialty chemicals, such as surfactants, emulsifiers, and performance additives, that are used as raw materials in various industries.

Sequent Scientific Ltd. Share Price

The Sequent Scientific Ltd. share price is a reflection of the company's performance and its future prospects. The share price is influenced by a variety of factors, including the financial performance of the company, industry trends, and market conditions.

Investors can track the Sequent Scientific Ltd. share price on our website and access price charts that provide a historical perspective on the stock's performance. Our pre-built screening tools allow investors to analyze the stock's performance based on various parameters, such as market capitalization, price-to-earnings ratio, dividend yield, and more.

Sequent Scientific Ltd. Balance Sheet

The balance sheet is an important financial document that provides a snapshot of a company's financial position at a specific point in time. The Sequent Scientific Ltd. balance sheet reflects the company's assets, liabilities, and shareholder equity.

Investors can access the Sequent Scientific Ltd. balance sheet on our website, along with other financial statements such as the profit and loss statement and cash flow statement. Our premium features allow investors to perform fair value calculations using tools such as DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Sequent Scientific Ltd. Annual Report

The Sequent Scientific Ltd. annual report provides a comprehensive overview of the company's financial performance, business operations, and future prospects. The annual report is a valuable resource for investors who want to gain insight into the company's strategy and growth prospects.

Investors can download the Sequent Scientific Ltd. annual report from our website to stay up-to-date with the company's performance and future plans.

Sequent Scientific Ltd. Dividend

The Sequent Scientific Ltd. dividend is a reflection of the company's financial performance and its commitment to shareholders. The company has a track record of consistently paying dividends to its shareholders.

Investors can access information on the Sequent Scientific Ltd. dividend on our website and track the dividend yield and payout ratio. Our screening tools allow investors to screen stocks based on dividend yield, payout ratio, and other parameters.

Sequent Scientific Ltd. Quarterly Result

The Sequent Scientific Ltd. quarterly result is an important indicator of the company's financial performance and its ability to meet its short-term goals. The quarterly result includes information on the company's revenue, profit, and other key financial metrics.

Investors can access the Sequent Scientific Ltd. quarterly result on our website and analyze the company's performance using our premium features. Our fair value calculation tools allow investors to estimate the intrinsic value of the stock based on various financial parameters.

Sequent Scientific Ltd. Stock Price

The Sequent Scientific Ltd. stock price is influenced by market conditions, industry trends, and the company's financial performance. Investors can access the latest information on the stock price on our website and track historical trends using our price charts.

Our pre-built screening tools allow investors to screen stocks based on various parameters, such as market capitalization, price-to-earnings ratio, and dividend yield. Investors can use these tools to identify stocks that meet their investment criteria.

Sequent Scientific Ltd. Price Chart

The Sequent Scientific Ltd. price chart is a valuable resource for investors who want to track the stock's performance over time. The price chart provides a historical perspective on the stock's price movements and helps investors identify trends and patterns.

Investors can access the Sequent Scientific Ltd. price chart on our website and customize it based on their preferences. Our premium features allow investors to perform technical analysis using tools such as moving averages, Bollinger bands, and relative strength index.

Sequent Scientific Ltd. News

Investors can stay up-to-date with the latest news on Sequent Scientific Ltd. on our website. Our news section provides information on the company's business operations, financial performance, and other key developments.

Investors can use this information to make informed investment decisions and stay ahead of market trends.

Sequent Scientific Ltd. Concall Transcripts

Sequent Scientific Ltd. provides concall transcripts for investors who want to gain insights into the company's management and strategy. The concall transcripts provide information on the company's financial performance, business operations, and future prospects.

Investors can access the Sequent Scientific Ltd. concall transcripts on our website and gain valuable insights into the company's strategy and growth prospects.

Sequent Scientific Ltd. Investor Presentations

Investor presentations are a valuable resource for investors who want to gain insights into a company's strategy and growth prospects. The Sequent Scientific Ltd. investor presentations provide information on the company's financial performance, business operations, and future plans.

Investors can download the Sequent Scientific Ltd. investor presentations from our website and stay up-to-date with the company's strategy and growth prospects.

Sequent Scientific Ltd. Promoters

Sequent Scientific Ltd. has a strong group of promoters who are committed to the company's growth and success. The promoters bring their expertise and experience to the table and provide strategic guidance to the company.

Investors can access information on the Sequent Scientific Ltd. promoters on our website and gain insight into their background and experience.

Sequent Scientific Ltd. Shareholders

Sequent Scientific Ltd. has a diverse group of shareholders who are committed to the company's growth and success. The shareholders include institutional investors, retail investors, and other stakeholders.

Investors can access information on the Sequent Scientific Ltd. shareholders on our website and gain insight into their investment patterns and strategies.

Read More
X